Study guide

15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

Key Takeaways Explain This Topic AI

Combined hormonal contraception is unacceptable with migraine with aura, smoking 15 or more cigarettes a day at 35 or older, BP of 160/100 or more, VTE, or under 21 days postpartum.

Enzyme inducers such as carbamazepine and rifampin reduce hormonal contraceptive efficacy; IUDs or injectable medroxyprogesterone are preferred.

The copper IUD (up to 7 days) is the most effective emergency contraception, ulipristal keeps efficacy to 120 hours, and levonorgestrel works best within 72 hours.

Menopausal hormone therapy is most favourable before 60 or within 10 years of menopause, with a progestogen if the uterus is present; transdermal estrogen has lower VTE risk.

Alpha-blockers relieve BPH within days but can cause floppy iris syndrome; 5-alpha-reductase inhibitors take 6 to 12 months and halve PSA; PDE5 inhibitors are contraindicated with nitrates.

Last updated: October 2026

Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

Pharmacists are often the most accessible health professional for sexual and reproductive health questions. In several provinces they prescribe hormonal contraception directly. This section covers contraceptive selection and safety, emergency contraception, menopause, preconception care, and common men's and bladder health problems.

  • 1. Hormonal Contraception
  • Combined Hormonal Contraceptives (Pill, Patch, Ring)

Mechanism: combined estrogen-progestin methods inhibit ovulation. Typical-use failure is about 7% a year, mainly because of missed doses.

Unacceptable risk (WHO and SOGC medical eligibility, category 4) , which means progestin-only or non-hormonal methods instead:

  • smoking 15 or more cigarettes a day at age 35 or older ;
  • migraine with aura ;
  • blood pressure of 160/100 mmHg or higher ;
  • past or current VTE, or a known thrombogenic mutation;
  • ischemic heart disease or stroke;
  • current breast cancer;
  • less than 21 days postpartum ;
  • severe liver disease or liver tumours;
  • complicated valvular heart disease;

lupus with antiphospholipid antibodies.

Common early effects: breakthrough bleeding (usually settles within 3 months), nausea and breast tenderness.

Missed combined pills (simplified SOGC approach):

Take the most recent missed pill as soon as possible, even if that means 2 pills in one day.

If 2 or more consecutive active pills are missed, use condoms or abstain until 7 consecutive active pills have been taken.

Missed in the first week (after the hormone-free interval) with unprotected sex in the previous 5 days: consider emergency contraception.

Missed in the third week: skip the hormone-free interval and start the next pack.

Progestin-Only and Long-Acting Methods

Progestin-only pills: norethindrone 0.35 mg must be taken within the same 3-hour window every day. Drospirenone 4 mg has a 24-hour window.

Injectable medroxyprogesterone every 13 weeks: delayed return of fertility and reversible bone-density loss.

Long-acting reversible contraception (LARC) is the most effective, with under 1% failure a year: the etonogestrel implant, the levonorgestrel intrauterine system, and the copper IUD .

Interactions

Enzyme inducers reduce hormonal contraceptive efficacy: rifampin and rifabutin, carbamazepine, phenytoin, phenobarbital, topiramate (higher doses), St. John's wort, and some antiretrovirals. Recommend an IUD (copper or levonorgestrel) or injectable medroxyprogesterone, or add condoms during use and for 28 days after stopping the inducer.

Other antibiotics (for example, amoxicillin and doxycycline) do not reduce contraceptive efficacy.

Estrogen lowers lamotrigine levels, so seizure control can change when a combined contraceptive is started or stopped.

2. Emergency Contraception (EC)

Method Access Timing Key points

Levonorgestrel 1.5 mg single dose Non-prescription (Schedule III) As soon as possible, within 72 hours; some effect up to 120 hours Efficacy falls with time and may be lower at higher body weight. Spotting and a changed next period are common

Ulipristal acetate 30 mg single dose Prescription (pharmacist-prescribable in some provinces) Up to 120 hours, with efficacy maintained better over time More effective than levonorgestrel. Wait 5 days after ulipristal before starting or resuming hormonal contraception, and use condoms meanwhile

Copper IUD Insertion by a clinician Up to 7 days Most effective ; unaffected by body weight; provides ongoing contraception

Counselling:

EC does not protect against later unprotected sex in the same cycle.

Spotting can occur, and the next period may be early or late.

Take a pregnancy test if the period is more than about 7 days late .

Start regular contraception and discuss STI testing.

Conscientious objection: a pharmacist who objects to providing EC must still ensure timely access, by directing the patient to a nearby pharmacy or provider that can help without delay. They do not refer the patient for an unnecessary medical assessment, and they do not leave the patient without options.

3. Preconception and Pregnancy

Folic acid: 0.4 mg daily, usually in a multivitamin, starting at least 3 months before conception and continuing through early pregnancy. Higher doses (1 to 4 mg) are advised by SOGC for people at increased risk of neural tube defects: a previous affected pregnancy, certain antiseizure drugs, diabetes, obesity or malabsorption.

Review teratogens before pregnancy: valproate, isotretinoin, warfarin, ACE inhibitors and ARBs, methotrexate, mycophenolate and statins (section 13.3).

4. Menopause

Menopausal hormone therapy (MHT) is the most effective treatment for hot flashes and night sweats. The benefit-risk balance is most favourable when started before age 60 or within 10 years of menopause .

Add a progestogen (or use a levonorgestrel IUS) if the patient has a uterus, to protect the endometrium.

Transdermal estrogen carries a lower VTE and stroke risk than oral estrogen.

Contraindications: breast cancer, VTE, coronary disease or stroke, unexplained vaginal bleeding, and active liver disease.

Genitourinary syndrome of menopause: low-dose vaginal estrogen has minimal systemic absorption and does not need a progestogen. Moisturizers and lubricants help too.

Non-hormonal options for hot flashes: SSRIs and SNRIs (venlafaxine, escitalopram, low-dose paroxetine), and gabapentin. Avoid paroxetine and fluoxetine with tamoxifen , because CYP2D6 inhibition reduces activation to endoxifen.

  • 5. Men's Health and Bladder Health
  • Benign Prostatic Hyperplasia (BPH)

Alpha-1 blockers (tamsulosin, silodosin, alfuzosin; doxazosin and terazosin need dose titration):

  • work within days;
  • cause dizziness and first-dose orthostatic hypotension ;

can cause intraoperative floppy iris syndrome , so patients should tell their eye surgeon before cataract surgery. Stopping the drug beforehand does not reliably prevent it.

5-alpha-reductase inhibitors (finasteride 5 mg, dutasteride):

  • shrink the prostate over 6 to 12 months ;
  • lower PSA by about 50% (double the measured value when interpreting);

should not be handled crushed or broken by people who are or may become pregnant.

Combination therapy is used for large prostates. Tadalafil 5 mg daily helps BPH symptoms, with or without erectile dysfunction.

Drugs that can precipitate urinary retention: anticholinergics, sedating antihistamines, decongestants and tricyclics.

Erectile Dysfunction

PDE5 inhibitors:

Sildenafil 25 to 100 mg about 1 hour before sex; a fatty meal delays its onset.

Tadalafil 10 to 20 mg as needed (effect up to 36 hours), or 5 mg daily.

Contraindicated with nitrates (no nitrate within 24 hours of sildenafil or vardenafil, or 48 hours of tadalafil) and with riociguat.

With alpha-blockers: start at a low dose once the alpha-blocker dose is stable.

Seek urgent care for an erection lasting more than 4 hours, or for sudden loss of vision or hearing.

New ED can be an early sign of cardiovascular disease.

Overactive Bladder and Incontinence

First line: bladder training, pelvic floor exercises, timed voiding, and less caffeine and evening fluids.

Review drug causes: diuretics (especially loop diuretics), sedatives, alpha-blockers in women, and cholinesterase inhibitors.

Antimuscarinics (oxybutynin, tolterodine, solifenacin, fesoterodine, darifenacin, trospium) cause dry mouth and constipation. They add to anticholinergic burden and can impair cognition, so avoid oxybutynin in older adults and people with dementia. Trospium crosses the blood-brain barrier least.

Mirabegron (a beta-3 agonist) avoids anticholinergic effects. Monitor blood pressure. It is a moderate CYP2D6 inhibitor.